June 2, 2024 08:00 AM EDT

Daiichi Sankyo, AstraZeneca say Enhertu works better than chemo in certain breast cancer patients

Lei Lei Wu

News Reporter

CHICAGO — Daiichi Sankyo and AstraZeneca’s antibody-drug conjugate Enhertu gave HER2-low breast cancer patients a median of 5 more months without cancer progression or death …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Daiichi Sankyo, AstraZeneca say Enhertu works better than chemo in certain breast cancer patients

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Dai­ichi Sankyo, As­traZeneca say En­her­tu works bet­ter than chemo in cer­tain breast can­cer pa­tients

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Daiichi Sankyo, AstraZeneca say Enhertu works better than chemo in certain breast cancer patients